Guided Therapeutics (GTHP) Cash from Investing Activities (2011 - 2022)
Guided Therapeutics (GTHP) reported Cash from Investing Activities of -$3000.0 for Q4 2022, up 25.0% on a YoY basis from -$2400.0 in Q4 2021, and up 78.57% sequentially from -$14000.0 in Q1 2022.
Guided Therapeutics (GTHP) Cash from Investing Activities (2011 - 2022) Analysis & Trends
Guided Therapeutics (GTHP) has 8 years of Cash from Investing Activities data on file, last reported at -$3000.0 in Q4 2022.
- For the quarter ending Q4 2022, Cash from Investing Activities rose 25.0% year-over-year to -$3000.0; the trailing twelve-month figure through Dec 2025 stood at -$3000.0 (up 82.35% YoY), and the FY2025 full-year result was -$2000.0, changed N/A from the prior year.
- Cash from Investing Activities rose to -$3000.0 in Q4 2022, from -$14000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$1000.0 in Q3 2020 to a low of -$14000.0 in Q1 2022.
- A 3-year average of -$4571.4 and a median of -$4000.0 in 2021 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 25.0% in 2022, while the deepest fall reached 1300.0% in 2022.
- Tracing GTHP's Cash from Investing Activities over 3 years: stood at -$1000.0 in 2020, then tumbled by 300.0% to -$4000.0 in 2021, then rose by 25.0% to -$3000.0 in 2022.
- Business Quant data shows GTHP's Cash from Investing Activities at -$3000.0 in Q4 2022, -$14000.0 in Q1 2022, and -$4000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.64 Bn | 176.34 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 129.04 Bn | 126.16 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 109.04 Bn | 99.82 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.54 Bn | 67.08 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.67 Bn | 45.00 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.40 Bn | 27.28 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 28.37 Bn | 26.08 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.92 Bn | 26.34 Bn | - | - |
| 9 | Koninklijke Philips | 25.48 Bn | 22.36 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Guided Therapeutics | 20.39 Mn | 20.32 Mn | 458,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -3,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Mar 31, 2022 | -14,000.00 |
| Mar 31, 2022 | -14,000.00 |
| Dec 31, 2021 | -4,000.00 |
| Dec 31, 2021 | -4,000.00 |
| Sep 30, 2021 | -5,000.00 |
| Sep 30, 2021 | -5,000.00 |
| Jun 30, 2021 | -4,000.00 |
| Jun 30, 2021 | -4,000.00 |
| Mar 31, 2021 | -1,000.00 |
| Mar 31, 2021 | -1,000.00 |
| Sep 30, 2020 | -1,000.00 |
| Sep 30, 2020 | -1,000.00 |
| Dec 31, 2015 | -6,000.00 |
| Dec 31, 2015 | -6,000.00 |
| Sep 30, 2015 | -2,000.00 |
| Sep 30, 2015 | -2,000.00 |
| Dec 31, 2014 | -6,000.00 |
| Dec 31, 2014 | -6,000.00 |